S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
NASDAQ:ETNB

89bio (ETNB) Stock Forecast, Price & News

$20.45
+0.46 (+2.30%)
(As of 06/6/2023 ET)
Compare
Today's Range
$19.28
$20.85
50-Day Range
$14.15
$20.45
52-Week Range
$2.91
$20.85
Volume
2.90 million shs
Average Volume
1.09 million shs
Market Capitalization
$1.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

89bio MarketRank™ Forecast

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
66.3% Upside
$34.00 Price Target
Short Interest
Healthy
9.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.15mentions of 89bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$41.02 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

502nd out of 982 stocks

Pharmaceutical Preparations Industry

236th out of 471 stocks


ETNB stock logo

About 89bio (NASDAQ:ETNB) Stock

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Stock News Headlines

SVB Securities Keeps Their Buy Rating on 89bio (ETNB)
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
89bio (NASDAQ: ETNB)
89bio (NASDAQ:ETNB) Stock Price Up 3.3%
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
89bio (ETNB) Investor Presentation - Slideshow
89bio (NASDAQ:ETNB) Reaches New 12-Month High at $18.88
89bio, Inc. (NASDAQ:ETNB) Insider Sells $247,799.13 in Stock
89bio (NASDAQ:ETNB) Stock Price Down 6.1%
Brokerages Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $32.22
Short Interest in 89bio, Inc. (NASDAQ:ETNB) Increases By 44.0%
89bio (NASDAQ:ETNB) Trading 3.1% Higher
89bio, Inc. (NASDAQ:ETNB) Short Interest Up 8.5% in March
See More Headlines

ETNB Price History

ETNB Company Calendar

Last Earnings
3/10/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+66.3%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-102,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
69,662,000
Market Cap
$1.49 billion
Optionable
Not Optionable
Beta
0.76

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 56)
    CEO & Director
    Comp: $829.41k
  • Mr. Quoc Le-Nguyen (Age 54)
    Chief Technical Operations Officer & Head of Quality
    Comp: $571.12k
  • Dr. Harry Mansbach M.D. (Age 57)
    Chief Medical Officer
    Comp: $603.22k
  • Mr. Ryan Stephen Martins (Age 44)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan (Age 56)
    Sr. VP of Fin. & Principal Accounting Officer
  • Ms. Melissa Abel
    Sr. VP of Commercial Strategy & Communications
  • Ms. Amanda Hill
    VP of People & Culture
  • Ms. Yun Bai
    VP & Head of CMC
  • Mr. Paul Shin
    Sr. VP of R&D Operations













ETNB Stock - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price forecast for 2023?

7 Wall Street analysts have issued 12-month target prices for 89bio's shares. Their ETNB share price forecasts range from $24.00 to $50.00. On average, they expect the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2023?

89bio's stock was trading at $12.73 at the start of the year. Since then, ETNB shares have increased by 60.6% and is now trading at $20.45.
View the best growth stocks for 2023 here
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) issued its earnings results on Friday, March, 10th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.15.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

(ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

Who are 89bio's major shareholders?

89bio's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.21%), Federated Hermes Inc. (3.49%), Suvretta Capital Management LLC (3.03%), Boxer Capital LLC (2.88%), BVF Inc. IL (2.53%) and BlackRock Inc. (1.71%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Longitude Capital Partners Iii, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $20.45.

How much money does 89bio make?

89bio (NASDAQ:ETNB) has a market capitalization of $1.49 billion. The company earns $-102,030,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.

This page (NASDAQ:ETNB) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -